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CD4+ and CD8+ Tlymphocytes arepowerful components of adaptive immunity, which essentiallycontributeto theelimination of
tumors.Duetotheircytotoxiccapacity,Tcellsemergedasattractivecandidatesforspeciﬁcimmunotherapyofcancer.Apromising
approach is the genetic modiﬁcation of T cells with chimeric antigen receptors (CARs). First generation CARs consist of a binding
moiety speciﬁcally recognizing a tumor cell surface antigen and a lymphocyte activating signaling chain. The CAR-mediated
recognition induces cytokine production and tumor-directed cytotoxicity of T cells. Second and third generation CARs include
signal sequences from various costimulatory molecules resulting in enhanced T-cell persistence and sustained antitumor reaction.
Clinical trials revealed that the adoptive transfer of T cells engineered with ﬁrst generation CARs represents a feasible concept for
the induction of clinical responses in some tumor patients. However, further improvement is required, which may be achieved by
second or third generation CAR-engrafted T cells.
1.Introduction
T-cell-based immunotherapy of tumors has gained much
impetus by the ﬁnding that CD8+ cytotoxic T cells (CTLs)
display a high capability to recognize and destroy malignant
cells, which present peptides derived from tumor-associated
antigens (TAAs) in a complex with the major histocompati-
bilitycomplex(MHC)classImolecules[1].CD4+ Tcellsrec-
ognizing peptides in the context of MHC class II molecules
also play an important role in antitumor immunity [2].
CD4+ T cells improve the capacity of dendritic cells (DCs) to
induce CTLs by the interaction between CD40 on DCs and
CD40 ligand on activated CD4+ T cells. Furthermore, CD4+
T cells provide help for the maintenance and expansion
of CTLs by secreting cytokines such as interleukin- (IL-)
2, and in addition they can eradicate tumor cells directly.
The presence of TAA-speciﬁc and tumor-reactive T cells in
peripheral blood of tumor patients has given rise to the
concept of adoptive cell therapy (ACT), a promising but
also challenging approach for tumor treatment [3]. In the
meantime, in vitro activation, expansion, and reinfusion
of TAA-speciﬁc autologous T cells have been successfully
applied for the treatment of virus-associated infections as
well as viral and nonviral malignancies [3–6]. In partic-
ular, the infusion of autologous tumor-inﬁltrating T cells
after lymphodepletion emerged as an attractive treatment
modality for patients with metastatic melanoma [7]. Despite
these promising eﬀects the clinical eﬃciency of ACT for
tumor patients is still limited. In addition, the isolation and
expansion of naturally occurring TAA-speciﬁc T-cell clones
is technically diﬃcult, labor-intensive, and time consuming.
Therefore, further improvement of current strategies based
on the adoptive transfer of tumor-reactive T cells is required.
A promising approach to generate large populations of
polyclonal T cells with a deﬁned speciﬁcity for TAAs in a
relatively short time is the genetic modiﬁcation of T cells2 Journal of Biomedicine and Biotechnology
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Figure 1: Principles of CAR architecture. CARs consist of a binding
moiety,anextracellularhingeandspacerelement,atransmembrane
region (TM), and the signaling endodomain. Commonly the
binding moiety consists of scFv derived from a TAA-speciﬁc
monoclonal antibody and the signaling domain(s) come(s) from
activating and costimulatory immune receptors.
using viral or nonviral transduction systems. One strategy
usesnaturalT-cellreceptor(TCR)αβheterodimersofknown
speciﬁcity and aﬃnity for TAAs [8, 9]. However, it has
been argued that formation of chimeric TCRs by pairing
of endogenous and transgenic TCR chains may lead to
de novo receptor speciﬁcities reacting against autologous
MHC-peptide complexes and thereby mediate autoimmune
reactions. Another general limitation of this approach is that
each transgenic TCR is speciﬁc for a certain MHC-peptide
complex and therefore is only suitable for MHC-matched
tumor patients. Moreover, various immune evasion mech-
anisms of tumors such as the downregulation of diﬀerent
components of the MHC class I processing and presentation
machinery might limit the success of this approach [10].
In an attempt to extend the recognition speciﬁcity of T
lymphocytesbeyondtheirclassicalMHC-peptidecomplexes,
a gene-therapeutic strategy has been developed that allows
redirecting T cells to deﬁned tumor cell surface antigens.
This strategy uses both the cellular and humoral arm of
the immune response by assembling an antigen-binding
moiety, most commonly a single chain variable fragment
(scFv) derived from a monoclonal antibody, together with
anactivatingimmunereceptor(Figure 1).Oncethisartiﬁcial
immune receptor is expressed at the surface of a modiﬁed
T lymphocyte, upon binding of the scFv to its antigen an
activating signal is transmitted into the lymphocyte, which
in turn triggers its eﬀector functions against the target cell
(Figure 2). In the ﬁrst attempts to reconﬁgure T cells with
antibody speciﬁcity the variable parts of the TCR α and
β chains were replaced with scFv fragments derived from
monoclonal antibodies. These hybrid T-cell receptors were
functionally expressed and recognized the corresponding
antigens in a non-MHC-restricted manner [11–13]. As a
consequence of the ﬁnding, that CD3ζ chain signaling on
its own is suﬃcient for T-cell activation [14, 15], the ﬁrst
“true” chimeric single-chain receptors were created by fusing
a scFv directly to the CD3ζ chain [16]. At that time this
concept was called the “T body approach” [17]. Nowadays
these types of artiﬁcial lymphocyte signaling receptors are
commonly referred to as chimeric immune receptors (CIRs)
or chimeric antigen receptors (CARs). The use of CARs to
redirect T cells speciﬁcally against TAA-expressing tumor
cells has a number of theoretical advantages over classical
T-cell-based immunotherapies. In contrast to the long-
lasting procedure of in vitro selection, characterization, and
expansion of T-cell clones with native speciﬁcity for MHC-
tumorpeptide complexes,geneticmodiﬁcation ofpolyclonal
T-cell populations allows to generate TAA-speciﬁc T cells in
o n et ot w ow e e k s[ 18] .E n g r a f t m e n tw i t hC A R se n a b l e sT
cells to MHC-independent antigen recognition (Figure 2);
thus major immune escape mechanisms of tumors such as
downregulation of MHC molecules are eﬃciently bypassed
[19]. Furthermore, proliferation and survival of modiﬁed
T cells can be improved by the implementation of a
multitude of signaling domains from diﬀerent immune
receptors in a single CAR (Figure 3). In addition, T cells
can be rendered more resistant against the immunosup-
pressive milieu in tumor tissue (Figure 3). In addition to
cancer immunotherapy, CAR-modiﬁed lymphocytes have
beensuccessfullyappliedforthetreatmentofvirusinfections
[20, 21], and more recently, ﬁrst experimental studies have
been published using CARs engrafted on regulatory T cells
(Tregs) for the treatment of autoimmune diseases [22–24].
First clinical studies using CAR-modiﬁed T cells have been
reported and a number of clinical trials are on the way.
At this translational point towards a clinical application
of CAR-modiﬁed T cells, this review summarizes various
experimental approaches towards an improvement of CARs
and discusses the prospects and future challenges using this
immunotherapeutic strategy for cancer treatment.
2. Designof ChimericAntigen Receptors
The general design of a CAR consists of a binding moiety,
an extracellular hinge and spacer element, a transmembrane
region, and the signaling endodomain (Figure 1). Com-
monly, the binding moiety consists of a scFv, comprising
the light (VL)a n dh e a v y( VH) variable fragments of a TAA-
speciﬁc monoclonal antibody joined by a ﬂexible linker.
Using such scFvs, T cells have been successfully redirected
against TAAs expressed at the surface of tumor cells from
various malignancies including lymphomas and solid organ
tumors. An extensive overview of TAAs used as targets for
CAR-modiﬁed T cells has been recently published by Sade-
lain and colleagues [25]. A major advantage of endowing T
cells with non-MHC-restricted, antibody-derived speciﬁcity
is that the potential target structures are no longer restricted
to protein-derived peptides, but rather comprise every
surface molecule on tumor cells including proteins with
varying glycosylation patterns and nonprotein structures
like gangliosides or carbohydrate antigens [26–29]. Thus,
the panel of potential tumor-speciﬁc targets is enlarged.Journal of Biomedicine and Biotechnology 3
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Figure 2: Antitumor eﬀects mediated by CAR-engrafted T cells. CAR-modiﬁed T cells can recognize tumor cells via binding of the CAR
to its TAA independent of TCR-MHC/Peptide interactions. As a result T cells are activated and can eﬃciently eliminate tumor cells by the
secretion of perforin and granzymes as well as the expression of FasL and tumor necrosis factor-related apoptosis inducing ligand (TRAIL).
In addition, other tumor-inﬁltrating immune cells can be activated by the secretion of various cytokines.
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Figure 3:EvolutionofCARsignalingcapacities.FirstgenerationCARstransmittedactivatingsignalsonlyviaITAM-bearingsignalingchains
like CD3ζ or FcεRIγ, licensing the engrafted T cells to eliminate tumor cells. Second generation CARs contain an additional costimulatory
domain (CM I), predominantly the CD28 domain. Signaling through these costimulatory domain leads to enhanced proliferation, cytokine
secretion,andrendersengraftedTcellsresistanttoimmunosuppressionandinductionofAICD.Recentdevelopmentsfusedtheintracellular
part of a second costimulatory molecule (CM II) in addition to CD28 and ITAM-bearing signaling chains, thus generating tripartite
signaling CARs. T cells engrafted with third generation CARs seem to have superior qualities regarding eﬀector functions and in vivo
persistence.
Other binding moieties than scFvs have also been introduced
into CARs and successfully used for predeﬁned targeting of
lymphocytes. For example, chimeric receptors incorporating
receptor ligands like a vascular endothelial growth factor
polypeptide, an integrin-binding peptide, heregulin, or an
IL-13 mutein have been explored and tumor regression was
demonstrated in mouse models [30–34]. Another group
has successfully retargeted murine and human lymphocytes
against hematopoetic tumors using a chimeric NKG2D
receptor fused to the CD3ζ chain [35–37]. The human
NKG2D receptor recognizes several stress proteins like MHC
class I chain-related (MIC) A/B and UL16 binding proteins
(ULBP) upregulated in a number of tumor cells [38, 39].
Therefore, such an approach can be applied for a wide
range of malignancies. One disadvantage of the classical
CAR strategy using scFvs or other binding moieties is the
limitation of appropriate surface antigens on tumor cells.
One alternative possibility is the isolation of MHC-tumor
peptide-speciﬁc antibodies from phage display libraries and
their subsequent in vitro evolution resulting ﬁnally in high
aﬃnity scFvs, which then can be engrafted on T cells as part
of a CAR [40].4 Journal of Biomedicine and Biotechnology
Cellular activation through chimeric receptors diﬀers
from signaling triggered by natural TCRs in the way that
binding aﬃnities of the commonly used IgG-derived scFvs
are several magnitudes higher than TCR aﬃnities for MHC-
peptide complexes [41, 42]. So far, no general a priori rules
can be deﬁned for the functionality of any given binding
moiety used in the context of a CAR. The magnitude
of the cellular response of CAR-redirected T cells against
antigen-expressing cells depends on a number of mutual
interacting factors like the binding aﬃnity of the scFv
itself [43, 44], the eﬀectiveness of surface expression of the
CAR on the eﬀe c t o rc e l la sw e l la sa n t i g e nd e n s i t y ,a n d
accessibility of the epitope on the target cell [44–47]. An
analysis of several scFvs with varying aﬃnity for the same
epitopes as parts of an otherwise similar CAR has shown
that immunoreceptors with binding aﬃnities below a Kd
of ∼10−8 activate engrafted T cells with similar eﬃciency
irrespectively of antigen density on target cells [43]. Another
study, however, stated that under suboptimal expression
levels of both CAR and antigen, a high-aﬃnity scFv (Kd <
10-8)i sl e s se ﬃcient than a low-aﬃnity scFv (Kd ∼ 10
−6)i n
redirecting CAR-engrafted lymphocytes against tumor cells
[44]. In a simpliﬁed way, one could argue that the aﬃnity
of the binding moiety must be high enough to establish an
immunological synapse, which engages a certain number of
activating immune receptors breaking the signal threshold
for the initiation of cytotoxic eﬀector functions. However,
if binding of the eﬀector cell to its target is too strong, the
eﬀector cell might strongly adhere to the target cell and is
therefore unable to engage subsequently other target cells,
thus limiting the overall antitarget eﬀect [48]. A relative
overexpression of a CAR in combination with high antigen
density can even induce T-cell apoptosis rather than T-cell
activation [46], although this might only hold true for CARs
without costimulatory capacities. Besides the binding of the
CAR itself to its antigen, the interaction of adhesion and
accessory molecules at the surface of eﬀector and target
cells contributes to the formation of an immunological
synapse and inﬂuences the overall antitarget eﬀect [49].
One important consequence of these analyses is that CARs
endowed with scFvs having reasonably low aﬃnities should
be able to discriminate between cells with low and high
antigen expression at the surface and therefore enable the
targeting of antigens, which are not tumor-speciﬁc, but
rather overexpressed by malignant cells [43, 46, 50]. Some
TAAs are shed from tumors and found in soluble form in
patients sera. Importantly, CAR-mediated T-cell response
is not inhibited by the presence of soluble antigens, which
would be otherwise a major limitation for the clinical
application [50, 51].
Most CARs comprise a hinge region between the binding
and the transmembrane domain. The rationale for including
a spacer region is to provide more ﬂexibility and accessibility
for the binding moiety, which might be otherwise buried by
the dense glycocalyx shell covering T cells [52]. Examples
of extracellular spacer regions include immunoglobulin
domains like the fragment crystallizable (Fc) regions of
antibodies [49, 53–55] or immunoglobulin-like domains
derived from the extracellular portions of CD8α, CD28,
TCRβ chain, or NKG2D [30, 35–37, 56–58]. Varying
spacer regions within otherwise similar CARs can result
in signiﬁcant diﬀerences in cytokine secretion and killing
eﬃciency of the modiﬁed T cells [59]. The requirement for
a spacer region for eﬃcient antigen recognition by CAR-
engrafted lymphocytes seems to depend on the epitope
position in the relevant antigen. Membrane-distal epitopes
can be well engaged by CARs without extracellular spacer
elements, whereas CARs equipped with scFvs recognizing a
membrane-proximal epitope need a protruding hinge region
for eﬃcient activation of the engrafted lymphocytes [60,
61]. The transmembrane region of CARs is in most cases
derived from homo- or heterodimeric type I membrane
proteins like CD4, CD8, CD28, CD3ζ,o rF c εRIγ [16,
49, 54, 56–58, 62]. A remarkable exception is a chimeric
immunreceptor incorporating the full murine, respectively,
human NKG2D receptor fused to the corresponding CD3ζ
chain. As NKG2D is a type II membrane protein, the
signaling domain of CD3ζ had to be fused to the N-terminus
of the chimeric receptor. Once the adaptor protein DAP10
was coexpressed in the engrafted cells, the recombinant
receptor was expressed at the surface in a suﬃcient way [35–
37].
Extraordinary attention has been paid to the intracellular
signaling domains of chimeric receptors. The ﬁrst generation
of CARs only contains a single signaling unit, in most
cases derived from the CD3ζ chain or the FcεRIγ [17,
63]. Several studies addressed the question, whether the
TCRζ chain, containing three immunoreceptor tyrosine-
based activation motifs (ITAMs), performs better than the
FcεRIγ (-Fcγ) chain with a single ITAM in context of a
CAR. Some studies reported that recombinant γ-a n dζ-
chain immunoreceptors activate grafted peripheral blood
T cells with similar eﬃciency [17, 64]. However, an in
vivo study demonstrated the superior tumor eradication
eﬃciency of T cells equipped with a CD3ζ-receptor com-
pared to a Fcγ-receptor [65]. An explanation for this
discrepancy might be the diﬀerent time frame of analysis
in these studies. Although Fcγ-receptors have initially a
higher surface expression than CD3ζ-receptors and activate
primary human T cells in a comparable manner, over time
the activation potential of the Fcγ receptor seems to be
more rapidly lost than CD3ζ-receptors [66]. The same
author, however, observed that surface expression of CD3ζ-
receptors is impaired by the intracellular portion of the
CD3ζ chain [66], a ﬁnding which is supported by the results
o far e c e n ts t u d y[ 67]. Nevertheless, over the past decade,
CARs with single signaling units against a wide variety of
TAAs have been successfully engrafted on native murine
and human T cells including T cells from tumor patients
[62, 68] and proved their antitumor eﬃciency both in vitro
and in vivo [10, 25]. Using immunocompromised mice
strains challenged with xenografts either subcutaneously or
orthotopically implanted, signiﬁcant reduction in tumor
growth or eradication could be shown for various tumor
entities like B-cell lymphoma [69–71], colon carcinoma [72,
73], erb2-positive carcinomas [74], ovarian cancer [75, 76],
prostate cancer [77–79], medulloblastoma [32, 80], and
glioma [33].Journal of Biomedicine and Biotechnology 5
3.ImprovingSignalingCapacities- Secondand
Third Generation CARs
Although ﬁrst generation CARs could initiate a cytotoxic
antitumor response in grafted T cells, it soon became
obvious that signals from ITAM-bearing receptors alone
can only induce transient cell division and suboptimal
cytokine secretion [81, 82] but cannot provide prolonged
polyclonal expansion and sustained antitumor reaction in
vivo. According to the prevailing two-signaling model for
lymphocyte activation, full activation and proliferation of
T cells require a costimulatory signal through CD28-B7
interaction in addition to signaling through the TCR/CD3
complex [83]. Providing the costimulatory signal in trans
through B7-expressing cells sustained proliferation of single
ITAM-bearing CAR-expressing lymphocytes and lead to
enhanced antitumor response in mouse models [68, 84]. A
more straight forward strategy comprised the CD28 signal-
ingintheCARconcept,eitherintwoseparatemolecules[85]
or combined in a single CD28-ITAM receptor fusion protein
[53, 86]. Placement of the CD28 domain proximal to the
CD3ζ chain and immediately distal to the transmembrane
domain resulted in good surface expression, whereas in the
opposite way the surface expression seems to be inhibited
[87]. Therefore, all published second generation CARs
follow the general outline TM domain-CD28-ITAM-bearing
signaling chain (Figure 3). Subsequently, it has been shown
that the synergistic action of the two signaling domains in
one single CAR resulted in sustained proliferation of grafted
lymphocytes [88, 89], increased levels of IL-2 [90, 91],
interferon(IFN)-γ [73,90,91],andgranulocytemacrophage
colony-stimulatingfactor(GM-CSF)secretion[73]indepen-
dent of exogenous B7/CD28 costimulation. Due to CD28
costimulation the expression of antiapoptotic proteins like
B-cell lymphoma- (Bcl-) 2 is upregulated and induction of
activation induced cell death (AICD) is delayed [92, 93].
Studies in mouse models ﬁnally supported the in vitro
ﬁndings that T cells grafted with recombinant CD28-ITAM
receptors have also higher proliferation capacities resulting
in an enhanced antitumor activity [73, 93–96]. A trans-
genic mouse model proved that even na¨ ıve resting T cells
can become fully activated, proliferate in antigen-induced
manner, and secrete IL-2 through a chimeric receptor
incorporating the costimulatory CD28 sequences in addition
to an activating ITAM receptor chain [97]. One major
drawback oﬀ cellular immunotherapy might be that adop-
tively transferred cells are rapidly impaired in their eﬀector
function by the immunosuppressive milieu, which tumor
cells create in their surroundings [98]. However, engrafting
T cells with second generation CARs increases substantially
the threshold of the modiﬁed cells against inhibitory eﬀects
mediated by transforming growth factor-β [99, 100]a n d
against the suppressive action of Tregs [100]. Resistance
to these cells is an important issue for immunotherapy,
as tumor-inﬁltrating Tregs counteract against adoptively
transferred tumor-speciﬁc T cells [101]. Another way of
improving signaling capacities is the incorporation of Src
family kinases or their adaptor molecules, which regulate the
very beginning of the signaling cascade resulting from TCR
triggering.The56kDaLckkinaseisoneoftheSrc-homology
kinases, which most likely phosphorylates CD3 ITAM motifs
after TCR engagement, and is noncovalently linked to either
theCD4orCD8molecule.Incorporationofthep56Lckorits
adaptor CD4 in a CAR with CD3ζ or CD28-CD3ζ signaling
chains decreased signaling threshold of receptor grafted T
cells [87].
In recent years, further costimulatory molecules from
the B7 family and the tumor necrosis factor receptor
superfamily came into the focus of research [102, 103].
Not surprisingly, a number of these molecules were also
tested in the context of CARs, leading to the development of
the third generation of CARs with three diﬀerent signaling
moieties in the intracellular chain (Figure 3). Brentjens et
al. generated a series of chimeric receptors bearing signaling
sequences from CD28, DAP10, CD134 (OX40), and CD137
(4-1BB) in addition to the CD3ζ chain [96]. However,
only the CD28-CD3ζ chain construct was able to induce
signiﬁcant proliferation of grafted T cells after antigen
contact independently of exogenous B7 costimulation. In
contrast, when cells expressing B7 molecules were used
as targets, all T cells grafted with CARs having CD3ζ
and costimulatory sequences proliferate better than those
cells grafted with CD3ζ CAR [96]. Also in terms of IL-
2a n dI F N - γ secretion T cells grafted with CD28-CD3ζ
CAR always out-competed T cells modiﬁed with receptors
having other signaling combinations [96]. Similar results
were obtained by another study, which also included the
inducible costimulator (ICOS) in the analyzed series of
signaling moieties [92]. Secretion of inﬂammatory cytokines
like tumor necrosis factor- (TNF-) α,I F N - γ,a n dG M - C S F
was similar for T cells engrafted with CD28-CD3ζ and
ICOS-CD3ζ CARs; however, IL-2 secretion and induction of
proliferation was better with the CD28-CD3ζ construct [92].
Thus, both studies have proven that for antigen-induced
proliferation and high-level cytokine secretion the signal
fromCD28isrequiredandsuﬃcient,butinclusionoffurther
costimulatory molecules enhances proliferation capacities
and apoptosis resistance in the grafted T cells [104]. It is now
established that physiologically optimal activation requires
CD28 engagement followed by costimulation through other
T-cell signaling molecules [105]. Consequently, CARs which
can simultaneously transmit multitude signals from CD28,
CD3ζ, and an additional costimulatory molecule in the
engrafted cell have been constructed. One of the most
important “secondary” costimulatory molecules is OX40
(CD134), for which studies have shown that its signaling can
furtheraugmentCD28-activatedT-cellresponses,enhancing
proliferation, cytokine secretion, and survival [106]. Inte-
gration of OX40 in a third generation CAR in combination
with CD28 and CD3ζ chain leads to sustained in vitro
proliferation and increased IL-2 secretion by grafted human
p r i m a r yTc e l l s[ 28]. A number of studies pointed out the
important role of the CD137/CD137L interaction for T-
cell survival and AICD resistance [107–109]. Integration
of CD137 signaling in CARs increased expression of anti-
apoptotic protein Bcl-xL, induced sustained proliferation
and survival of the grafted T cells, and was associated with
higher eﬀector cytokine production and antigen-speciﬁc6 Journal of Biomedicine and Biotechnology
tumor cell lysis [67, 110, 111]. In a mouse model, an
established xenograft was controlled by retargeted T cells
containing a CD28-CD137-CD3ζ CAR [112]. If targeted
cancer cells are B7.1/B7.2 positive, chimeric CD137-CD3ζ
CARs can be even more suﬃcient than a CD28-CD3ζ CAR
[110]. Despite these encouraging results, the use of CARs
with a tripartite signaling domain might also have its pitfalls.
It has to be carefully investigated, if CARs with tripartite
signaling moieties reduce the signal threshold to a level,
where activation of grafted T cells can occur without antigen
triggering. Signal leakage might turn out to be a problem for
clinical applications of third generation CARs.
4. Strivingfor Optimal Function of
Adoptively TransferredCAR-Modiﬁed Cells
Research in ACT for cancer focused on CD8+ eﬀector cells
for a long time, because this population mediates mainly
the cytotoxic eﬀector functions [3, 113]. Meanwhile, the
important function of CD4+ T helper cells for mounting
an eﬃcient antitumor response has been demonstrated
[114]. CD4+ T cells can be redirected in an MHC class
II-independent manner towards TAAs similar to CD8+ T
cells by engraftment with chimeric antigen receptors and
even converted to eﬃcient cytolytic eﬀector cells [115–
117]. The cytotoxic response is essentially mediated via the
perforin/granzyme pathway [116, Figure 2]. The cytokine
proﬁle after antigen-stimulation of CAR-engrafted CD4+ T
cells is more diverse compared to their CD8+ counterparts
by means of higher amounts of IL-2 and TNF-α and
exclusive IL-4, IL-6, and IL-10 secretion [110, 112]. In a
transgenic mouse model it has been shown that adoptive
transfer of CAR-grafted CD4+ and CD8+ T cells can reject
tumorburdensmuchmoreeﬃcientthanadoptivetransferof
grafted CD8+ T cells only [118]. Beside T cells expressing an
α/β T C R ,as m a l ls u b p o p u l a t i o no fl e s st h a n5 %o fh u m a n
blood T cells expresses an invariant γ/δ TCR. Subsets of
human γ/δ T cells recognize stress ligands also expressed by
tumor cells and therefore this T-cell population is another
attractive candidate for cellular immunotherapy [119]. γ/δ
T cells can be selectively expanded by administration of
aminobisphosphonates in vitro and genetically modiﬁed
with CARs using retroviral vector systems. CAR-grafted γ/δ
T cells secrete IL-2 and IFN-γ upon antigen stimulation and
are able to selectively kill TAA-expressing tumor cells [120].
In conclusion, not only CD8+ eﬀector cells should be taken
into account when deciding clinical application of adoptive
transfer of CAR-engineered T cells.
An important issue for the transfer of ACT to the clinic is
the in vitro cultivation and expansion of the CAR-modiﬁed
c e l l st oe n s u r es u ﬃcient cell numbers for the treatment [18].
Our current understanding of the development of na¨ ıve
CD4+ and CD8+ T cells after antigen-activation proposes
the generation of two main subsets of cells termed eﬀector
memory (TEM) and central memory T cells (TCM). The
development and diﬀerentiation of these two populations is
under intense investigation [121, 122]. Studies with various
mouse models have shown that these two T-cell subsets
are unequally suited for a successful adoptive transfer. TEM
have enhanced cytotoxic eﬀector function, but are sensitive
to AICD and persist only for short time in the host after
adoptive transfer, whereas administration of TCM results in
long-term memory response and eﬃcient tumor rejection
[123, 124]. In nonhuman primates, adoptive transfer of a
virus-speciﬁc CD8+ T-cell clone derived from CD62+ TCM
but not from CD62− TEM can also establish persistent T-
cell memory [125]. Thus, optimized culture conditions have
to be established, which preserve the functional phenotype
of TCM for CAR-engrafted T cells before adoptive transfer.
For long-term culture and expansion of T cells routinely
high doses of IL-2 were used, leading to the development
of late eﬀector cells less qualiﬁed for long-lasting antitumor
responses after adoptive transfer [126]. Recently, other
members of the IL-2 related cytokine family like IL-7, IL-
15, and IL-21 have raised considerable interest for their
potent eﬀect on activation and expansion of T cells [127–
129]. T cells grafted with a ﬁrst generation CAR could be
rapidly expanded in the presence of IL-15 and could better
control tumor growth after transfer in a tumor-bearing
immunocompromisedmousestrain[69].Transgenicexpres-
sion of a homeostatic cytokine like IL-7 or IL-15 or their
high-aﬃnity receptors in addition to a CAR in genetically
modiﬁed cells may be an option to ensure suﬃcient supply
with these cytokines in vivo [130, 131]. Another way to
improve in vitro expansion and in vivo persistence after
adoptive transfer is the engraftment of CARs in antigen-
speciﬁc T cells reactive against common viral infections like
Epstein-Barr virus (EBV) or cytomegalovirus (CMV). EBV-
speciﬁc T cells have been engrafted with CARs against B-cell
malignancies, and rapid expansion of genetically modiﬁed
cells could be driven by EBV-transformed B-lymphoblastoid
cell lines [132–134]. CAR-modiﬁed EBV-speciﬁc T cells
generated from healthy donors or tumor patients showed
antitumor eﬀects in xenograft mouse models [135, 136].
The condition of ex vivo generated CAR-modiﬁed T
cells is also highly inﬂuenced by the method chosen for the
genetic modiﬁcation. In general, retro- or lentiviral gene
transfer is widely used for this purpose. For retroviral gene
transfer, activation of T lymphocytes by TCR triggering
is a prerequisite, and also in case of lentiviral vectors
the transduction eﬃciency is highly increased in this way.
However, it has been argued that TCR activation impairs
the half-life, repertoire, and immune competence of the
transduced cells [137] .F u r t h e r m o r e ,as t u d yi nam o u s e
model revealed that eﬀector cells derived from na¨ ıve T
cells rather than from memory T cell subsets might be
better suited for ACT [138]. Therefore, preactivation via
TCR for transduction might reduce ﬁtness of engineered T
cells for adoptive transfer. In principal, T lymphocytes can
be transduced using lentiviral vectors without preactivation
preconditioning the T cells with stimulating cytokines like
IL-2, IL-7, or IL-15 [139]. Alternatively, diﬀerent nonviral
gene transfer methods have been evaluated for genetic
modiﬁcation of T cells with CARs. These methods might
be more cost eﬃcient and safety issues regarding the use
of viral vectors can be circumvented. Electroporation with
naked DNA has been successfully used for the modiﬁcationJournal of Biomedicine and Biotechnology 7
of na¨ ıve cord-blood cells with a CAR construct; however, a
constant selective pressure is necessary during the in vitro
prolongation of the modiﬁed cells to avoid transgene loss
[140]. In addition, transfection eﬃciency of nonviral gene
transfer is clearly less eﬃcient compared to transduction and
the ex vivo manufacturing time is considerably prolonged
to generate suﬃcient numbers of modiﬁed cells. During
this time cells might diﬀerentiate in exhausted late eﬀector
cells less suited for immunotherapy. Recently, T cells have
been electroporated with CAR encoding mRNA; however,
the surface expression of CARs was transient and rapidly
decreasing after a few days [141]. Other studies use diﬀerent
retrotransposon systems for the genetic modiﬁcation of
primary human T cells or umbilical cord blood T cells
with CARs and could demonstrate safe integration and
long-term expression of the transgene. However, initial
transfection eﬃciency was still very low and CAR-positive
T cells had to be expanded over several weeks to generate
suﬃcientnumbers[142–144].Atthepresentstage,viralgene
transfer seems to be the most feasible way to ensure stable
long-time expression of CARs in grafted cells; however, if
methods of nonviral gene modiﬁcation are improving in
terms of gene transfer rates and stability of expression, they
might become a safer and cheaper alternative for clinical
applications.
5. ClinicalStudies Based on
CAR-ModiﬁedTCells
Clinical studies based on the antitumor eﬀects of CAR-
engineeredTcellsinvitroandinvariousanimalmodelshave
been conducted to evaluate the potential of T cells modiﬁed
withﬁrstgenerationCARsforthetreatmentofpatients.Such
a clinical study was performed to evaluate the eﬃciency of T
cells modiﬁed with a CAR displaying CD4 as binding moiety
for the human immunodeﬁciency virus (HIV) envelope
fused to intracellular CD3ζ signaling chain in HIV-infected
patients [21]. Twenty-four HIV-positive patients received a
singleinfusionof2−3×1010 autologousgeneticallymodiﬁed
CD4+ and CD8+ T cells administered with or without IL-
2. Treatment was well tolerated and a persistence of the
CAR-engineered T cells was observed. Modiﬁed T cells were
detected in 1–3% of blood mononuclear cells at 8 weeks and
0.1% at 1 year after infusion. No signiﬁcant mean change in
plasma HIV RNA or blood proviral DNA was found.
More recently, ﬁrst clinical trials were conducted to
investigate the potential of CAR-modiﬁed T cells in tumor
patients. In one study, three patients with metastatic renal
cellcarcinoma(RCC)weretreatedwithTcellsmodiﬁedwith
a CAR recognizing carbonic anhydrase IX, which represents
a na n t i g e no v e r e x p r e s s e do nc l e a rc e l lR C C[ 145, 146]. IL-
2 was also administered subcutaneously. Infusions of the
CAR-modiﬁed T cells were initially well tolerated. However,
patients developed severe liver toxicities after four to ﬁve
infusions, which was probably due to a destruction of
carbonic anhydrase IX-expressing bile duct epithelial cells
by the CAR-modiﬁed T cells. No clinical responses were
observed.
In another clinical study, 14 patients with metastatic
ovarian cancer were treated with T cells grafted with an α-
folate receptor-speciﬁc CAR [147]. Gene-modiﬁed T cells
could be detected in the circulation in large numbers for the
ﬁrst two days after transfer, but then T-cell numbers rapidly
declined to be barely detectable one month later in most
patients. No clinical responses were found.
Whereas in the three clinical studies mentioned above
T cells were genetically engineered using retroviral vectors,
Park et al. reported on the adoptive transfer of T cells
electroporated with a plasmid encoding for a L1-cell adhe-
sion molecule-speciﬁc to neuroblastoma patients [148]. The
persistence of CAR-modiﬁed T cells in the circulation was
short in patients with bulky disease, but signiﬁcantly longer
in one patient with limited tumor burden. One of six treated
patients showed a partial response.
Till et al. conducted a clinical trial in which patients
with B-cell lymphoma or mantle cell lymphoma were treated
with T cells modiﬁed by electroporation with a plasmid
encoding a CD20-speciﬁc CAR [149]. Of seven patients, two
maintained a previous complete response, one displayed a
partial response, and four had stable disease.
In another clinical study, eleven neuroblastoma patients
weretreatedwithEBV-speciﬁcTcellsengineeredwithaCAR
recognizing the diasialoganglioside GD2 representing an
antigen expressed by neuroblastoma cells [150]. Treatment
was well tolerated. Four of eight patients with evaluable
tumors had evidence of tumor necrosis or regression,
including a sustained complete remission.
6. Conclusions
T cells play a major role in antitumor immunity. CD8+ CTLs
eﬃciently destroy tumor cells, whereas CD4+ T cells improve
the antigen-presenting capacity of DCs and support the
stimulationoftumor-reactiveCTLs.Followingtheseﬁndings
T-cell-based immunotherapeutic strategies for the treatment
of tumor patients were developed. A promising approach is
the genetic modiﬁcation of polyclonal CD4+ and CD8+ T
cells with CARs. First generation CARs consist of a binding
moiety speciﬁcally recognizing a tumor cell surface antigen
andalymphocyteactivatingsignaling chain.Tcellsmodiﬁed
with such CARs are capable of lysing tumor cells in vitro,
and the adoptive transfer of engineered T cells results in
tumor regressions in various mouse models. Recent clinical
studies which are based on the administration of CAR-
modiﬁed T cells to tumor patients revealed that this strategy
isfeasibleandsafe.Despitethesepromisingeﬀects,anumber
of obstacles have still to be overcome for a successful tumor
treatment with CAR-modiﬁed T cells. The immunogenicity
of CARs can restrict the duration of treatment and thus can
limit the overall antitumor eﬀect. The development of CAR-
speciﬁc antibodies, however, can be potentially avoided by
the use of humanized or human scFvs. Additional concerns
are related to unexpected oﬀ-target toxicities mediated by
CAR-engrafted T cells. Autoreactivity can be either induced
byCAR-engraftedTcellsrecognizingnormaltissuesexpress-
ing the target antigen or CAR-mediated activation of native8 Journal of Biomedicine and Biotechnology
autoreactive T cells. Another obstacle for immunothera-
peutic strategies based on CAR-engrafted T cells is the
limited availability of appropriate surface TAAs. Finally, the
short life-time of infused CAR-modiﬁed T cells results in
limited antitumor responses. In vivo persistence might be
prolonged by second or third generation CAR-engrafted T
cells displaying increased proliferation rates and cytokine
secretion, and which are more resistant to tumor-derived
immunosuppressivefactors.Currentlyseveralclinicalstudies
are launched using second generation CARs and the ﬁeld has
to await, if this strategy can transfer the promise for tumor
treatment from bench to bedside.
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